Icosapent ethyl for the treatment of severe hypertriglyceridemia

Hassan Fares1 Department of Hospital Medicine, Ochsner Medical Center, New Orleans, LA, USA

Carl J Lavie2 Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, LA, USA;3 Department of Preventive Medicine, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USACorrespondence[email protected]

James J DiNicolantonio4 Mid America Heart Institute at Saint Luke’s Hospital, Kansas City, MO, USA

James H O’Keefe5 Mid America Heart Institute, University of Missouri–Kansas City, Kansas City, MO, USA

Richard V Milani2 Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, LA, USA

Icosapent ethyl for the treatment of severe hypertriglyceridemia

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Icosapent ethyl for the treatment of severe hypertriglyceridemia

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date